echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > A new target for the treatment of the most common lung cancer

    A new target for the treatment of the most common lung cancer

    • Last Update: 2022-09-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    From left to right: Marselina Arshakyan, Elba Marín (front), Paula Duch, Cristina Teixidó, Noemí regart, Rafael Ikemori, Jordi Alcaraz, Marta Gabasa and Natalia Díaz



    Levels of the TIMP-1 protein in tissues and blood have been repeatedly shown to be associated with a poor prognosis for lung cancer, but its role in this cancer process remains unclear to this day


    "In recent decades, cancer research has aimed at providing more specific treatments for each type of tumor and patient, improving patient outcomes


    The study included the participation of researchers from


    A unique collection of fibroblasts of Spanish patient origin

    TIMP-1 is a protein abnormally secreted by fibroblasts, a non-malignant cell that accompanies cancer cells and is a major component of the so-called tumor microenvironment


    Interaction of Protumour with CD63 receptors

    The results first suggested that elevated TIMP-1 levels in lung cancer were due to the "pathological level" at which fibroblasts secreted this protein


    New treatment strategies

    These results may facilitate the development


    In this sense, the study, in addition to showing that fibroblasts play a very important role in tumor progression, also opens up a way to "attack this tumor axis": so-called anti-fibrotic drugs, developed to inhibit the pathological function


    Effects on other cancers

    These results may also be effective for other cancers, as the TIMP-1 protein is also widely described as a biomarker of poor prognosis in many types of solid tumors


    essay

    Aberrant TIMP-1 overexpression in tumor-associated fibroblasts drives tumor progression through CD63 in lung adenocarcinoma


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.